Covid 19 Cicada Variant UK: The Highly Mutated Strain That Health Officials Are Watching Very Closely

A virus variant named after an insect that vanishes underground for years and then reappears without warning has an almost poetic, if slightly unsettling, quality. The Cicada strain of COVID-19 has indeed earned its moniker. Health officials in the UK and at least 22 other countries are currently keeping an eye on BA.3.2, a strain that is descended from BA.3, a minor Omicron offshoot that briefly circulated in late 2021 and early 2022 before virtually disappearing from surveillance records. It appeared to be gone for a while. It wasn’t.

Long before the virus was officially discovered in South Africa in November 2024, genetic analysis indicates that it was quietly evolving between December 2023 and July 2024. This type of covert evolution, according to scientists, usually happens during long-term infections in immunocompromised people, where the virus has both time and pressure to adapt. In this instance, the outcome is a strain that has over 70 mutations in comparison to the original Wuhan strain and over 50 alterations in its spike protein alone in comparison to its BA.3 ancestor. That’s a lot by any standard. It is the type of mutational leap that scientists sometimes refer to as a saltation event; it is more of an abrupt genetic leap forward than a slow drift.

Silently, the Covid 19 Cicada variant made its way to the UK. In September 2025, the UK Health Security Agency discovered it for the first time in England. Public Health Wales verified its circulation in Wales by February 2026 and observed a rise in the percentage of this variant in sequenced cases. Health officials’ language has been carefully calibrated; it is neither dismissive nor alarming. A Public Health Wales spokesperson stated earlier this week that “overall COVID-19 activity remains within the range we would expect to see at this time of year,” adding that surveillance systems are in place to detect any significant shift. Depending on which sentence you choose to read first, that kind of statement can mean both everything and nothing at the same time.

What makes Cicada interesting is not necessarily what it is doing at the moment, but rather what its biology indicates it may be capable of. The variant is expected to become a dominant strain in the UK, according to Cambridge University professor Ravi Gupta, who advised the UK government during the worst of the pandemic. Additionally, he has highlighted a point that has not gotten nearly enough attention in the media: children may be more susceptible to the spread of Cicada because younger populations have less immunity to this specific viral lineage. It’s a subtle detail that is often overlooked in reports, but it’s worth taking a moment to consider.

The situation is already changing throughout Europe. Between November 2025 and January 2026, approximately 30% of sequenced COVID cases in Denmark, Germany, and the Netherlands were caused by Cicada. That figure is not on the periphery. Even though it hasn’t yet supplanted the dominant JN.1 descendants that have been circulating widely, this variant is gaining traction. They will just have to wait and see, as one American expert on infectious diseases stated with admirable candor. As has always been the case, the virus has little interest in assisting with forecasts.

Observing this from a UK perspective, it seems as though the public discourse regarding Covid variants has grown both more sophisticated and weary at the same time. People are familiar with the routine. Alpha, Delta, Omicron, JN.1, and a series of subvariants with blurring alphanumeric names have all passed through their lives. There is a specific type of fatigue brought on by the prospect of yet another highly mutated strain; it is neither panic nor indifference, but rather something in between. This general weariness may be a public health factor in and of itself, influencing how seriously warnings are received and how quickly people respond to them.

Although not conclusively so, the available data on severity is encouraging. There was no evidence of increased severity, hospitalizations, or deaths linked to Cicada in the WHO’s risk assessment from December 2025. As of February 2026, the CDC was keeping track of the variant’s spread throughout at least 25 states in the United States and reported no rise in severe illness nationwide. Vaccination still seems to offer significant protection against the outcomes that matter most: serious illness, hospitalization, and death. However, laboratory studies do indicate that current vaccines are less effective at neutralizing BA.3.2 than currently dominant strains—a Lancet study has documented this.

For those who are curious, the symptoms are generally in line with the results of Covid variants over the past few years. cough, fever, sore throat, exhaustion, dyspnea, and occasionally loss of smell or taste. The list also includes symptoms related to the digestive system. Some infections show no symptoms at all, which brings up the well-known and annoying issue of people spreading the virus without realizing they have it. Rest, hydration, over-the-counter medications for mild cases, and quick medical attention when symptoms worsen are still the fundamentals of managing it.

It’s difficult to ignore the fact that the UK is in a familiar situation: observing a variant emerge overseas, identifying it at home, tracking its spread, and waiting to see if it tips into something that necessitates a more forceful public response. The surveillance apparatus, which includes Public Health Wales, UKHSA, and WHO technical advisory groups, is operating as intended. At least that aspect has significantly improved since 2020. Now, the question is whether Cicada is another wave that is slowly building beneath the surface or if it fades away like BA.3 did before most people even knew what it was called.